Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Latham, Te"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-3 z 3
    Tytuł:
    A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
    Autorzy:
    Woolsey C; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Cross RW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Agans KN; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Borisevich V; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Deer DJ; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Geisbert JB; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Gerardi C; Department of Viral Vaccine Development, Auro Vaccines, Pearl River, New York, United States of America.
    Latham TE; Department of Viral Vaccine Development, Auro Vaccines, Pearl River, New York, United States of America.
    Fenton KA; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Egan MA; Department of Immunology, Auro Vaccines, Pearl River, New York, United States of America.
    Eldridge JH; Department of Immunology, Auro Vaccines, Pearl River, New York, United States of America.
    Geisbert TW; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America.; Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, United States of America.
    Matassov D; Department of Viral Vaccine Development, Auro Vaccines, Pearl River, New York, United States of America.
    Pokaż więcej
    Źródło:
    PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2022 May 27; Vol. 16 (5), pp. e0010433. Date of Electronic Publication: 2022 May 27 (Print Publication: 2022).
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Ebolavirus*
    Hemorrhagic Fever, Ebola*
    Marburg Virus Disease*/prevention & control
    Marburgvirus*
    Viral Vaccines*
    Animals ; Antibodies, Viral ; Glycoproteins ; Humans ; Macaca fascicularis ; Vaccines, Attenuated ; Vesiculovirus/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
    Autorzy:
    Elizaga ML; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Kochar NK; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Wilson GJ; Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
    Allen MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
    Tieu HVN; Laboratory of Infectious Disease Prevention, New York Blood Center, New York, New York, United States of America.
    Frank I; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States of America.
    Sobieszczyk ME; Division of Infectious Diseases, Columbia University Medical Center, New York, New York, United States of America.
    Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Sanchez B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
    Latham TE; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    Clarke DK; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    Egan MA; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    Eldridge JH; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    Hannaman D; Ichor Medical Systems, Incorporated, San Diego, California, United States of America.
    Xu R; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    Ota-Setlik A; Profectus BioSciences, Incorporated, Pearl River, New York, United States of America.
    McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.; Department of Global Health, University of Washington, Seattle, Washington, United States of America.; Department of Medicine, University of Washington, Seattle, Washington, United States of America.
    Hay CM; Infectious Diseases Division, University of Rochester Medical Center, Rochester, New York, United States of America.
    Pokaż więcej
    Corporate Authors:
    NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
    Źródło:
    PloS one [PLoS One] 2018 Sep 20; Vol. 13 (9), pp. e0202753. Date of Electronic Publication: 2018 Sep 20 (Print Publication: 2018).
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
    MeSH Terms:
    AIDS Vaccines/*administration & dosage
    Genetic Vectors/*administration & dosage
    Interleukin-12/*genetics
    Vaccines, Attenuated/*administration & dosage
    Vaccines, DNA/*administration & dosage
    Vesicular stomatitis Indiana virus/*genetics
    AIDS Vaccines/adverse effects ; Adult ; Combined Modality Therapy ; Double-Blind Method ; Electroporation ; Female ; Genetic Vectors/adverse effects ; HIV-1 ; Healthy Volunteers ; Humans ; Immunization, Secondary ; Injections, Intramuscular ; Male ; Middle Aged ; Plasmids/genetics ; Vaccines, Attenuated/adverse effects ; Vaccines, DNA/adverse effects ; Young Adult ; gag Gene Products, Human Immunodeficiency Virus
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Autorzy:
    Mire CE; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
    Matassov D; Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Geisbert JB; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
    Latham TE; Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Agans KN; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
    Xu R; Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Ota-Setlik A; Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Egan MA; Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Fenton KA; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
    Clarke DK; Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Eldridge JH; Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.; Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
    Geisbert TW; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
    Pokaż więcej
    Źródło:
    Nature [Nature] 2015 Apr 30; Vol. 520 (7549), pp. 688-691. Date of Electronic Publication: 2015 Apr 08.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Ebola Vaccines/*administration & dosage
    Ebola Vaccines/*immunology
    Ebolavirus/*immunology
    Hemorrhagic Fever, Ebola/*prevention & control
    Hemorrhagic Fever, Ebola/*virology
    Vaccines, Attenuated/*immunology
    Vesiculovirus/*genetics
    Africa, Western/epidemiology ; Animals ; Antibodies, Viral/immunology ; Democratic Republic of the Congo/epidemiology ; Ebola Vaccines/genetics ; Ebolavirus/classification ; Female ; Genetic Vectors/genetics ; Hemorrhagic Fever, Ebola/immunology ; Humans ; Immunoglobulin G/immunology ; Kinetics ; Macaca fascicularis ; Male ; Survival Analysis ; Vaccination ; Vaccines, Attenuated/administration & dosage ; Vaccines, Attenuated/genetics ; Vesiculovirus/growth & development
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-3 z 3

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies